HTHarry E. Taylor

Harry E. Taylor

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Harry E. Taylor has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Atanu K. Khatua

    Meharry Medical College, Center for AIDS Health Disparities Research, Nashville, Tennessee, United States of America

    1 shared publication
  • Craig W. Lindsley

    Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America

    1 shared publication
  • Glenn E. Simmons

    Department of Biomedical Sciences, College of Veterinary Medicine, Cornell University

    1 shared publication
  • H. Alex Brown

    Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee 37232

    1 shared publication
  • Richard T. D’aQuila

    Northwestern HIV Translational Research Center, Division of Infectious Diseases, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States of America

    1 shared publication
  • Thomas P. Mathews

    Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America

    1 shared publication

Latest Publications

  • Open Access

    Phospholipase D1 Couples CD4+ T Cell Activation to c-Myc-Dependent Deoxyribonucleotide Pool Expansion and HIV-1 Replication

    by Harry E. Taylor, Glenn E. Simmons, Thomas P. Mathews, Atanu K. Khatua, Waldemar Popik, Craig W. Lindsley, Richard T. D’aQuila, H. Alex Brown

    Quiescent CD4+ T cells restrict human immunodeficiency virus type 1 (HIV-1) infection at early steps of virus replication. Low levels of both deoxyribonucleotide triphosphates (dNTPs) and the biosynthetic enzymes required for their de novo synthesis provide one barrier to infection. CD4+ T cell activation induces metabolic reprogramming that reverses this block and facilitates HIV-1 replication. Here, we show that phospholipase D1 (PLD1) links T cell activation signals to increased HIV-1 permissivity by triggering a c-Myc-dependent transcriptional program that coordinates glucose uptake and nucleotide biosynthesis. Decreasing PLD1 activity pharmacologically or by RNA interference diminished c-Myc-dependent expression during T cell activation at the RNA and protein levels. PLD1 inhibition of HIV-1 infection was partially rescued by adding exogenous deoxyribonucleosides that bypass the need for de novo dNTP synthesis. Moreover, the data indicate that low dNTP levels that impact HIV-1 restriction involve decreased synthesis, and not only increased catabolism of these nucleotides. These findings uncover a unique mechanism of action for PLD1 inhibitors and support their further development as part of a therapeutic combination for HIV-1 and other viral infections dependent on host nucleotide biosynthesis. Replication of all human viruses depends on building blocks derived from the metabolic pathways of the infected host cell. The production of progeny virions requires synthesis of viral nucleic acids from deoxyribonucleotide triphosphates (dNTPs). HIV-1 infection in resting T cells is limited, at least in part, because the levels of critical nucleotides are low. However, stimulation of T cells turns on their metabolic machinery to increase c-Myc expression and subsequent synthesis of these key components of RNA and DNA, which augments HIV-1 replication. We have identified PLD1 as a key molecular switch that couples stimulatory T cell signals to c-Myc-dependent nucleotide biosynthesis. We also found that a small molecule that inhibits PLD1 suppresses HIV-1 replication by limiting c-Myc-dependent effects of T cell activation that support efficient HIV reverse transcription. Our study provides insight into a novel way of targeting T cell activation-induced processes such as nucleotide biosynthesis that has potential to augment current therapeutics for HIV-1.